I wasn’t planning on posting my progress to natural “T” production on a daily basis however, I did experience some changes yesterday that I thought may or may not be noteworthy. Ever since I started on Clomid which was approximately 10 days ago, I’ve noticed a pretty sharp decline in body weight. To be more specific I’ve dropped about 6 lbs in water weight. Water retention has been a huge issue for me ever since I started on TRT 3 years ago. There were days when I would step on the scale and weigh 220 in the morning and then 226 by the end of the day. And my diet is very good so it’s not as if I’ve been eating a bunch of fast food or anything that’s high in sodium. I should also mention that I’m 6”4 so at 220 I don’t consider myself over weight. I’m not a body builder but I do lift weights and do cardio on average 5 days a week.
The Clomid seemed to really help with the water retention which I know is due to the fact that it’s an estrogen blocker. Again over the last 10 days water weight has been way down and I haven’t been experiencing the flocculation in weight from morning to the evening. However, yesterday I did experience pretty heavy water retention. I gained about 5 lbs from my morning weigh to my evening. Also, felt very bloated and uncomfortable. I’ve been very consistent with my Clomid regimen, 50mg in the morning after breakfast and another 50mg’s in the evening after dinner, so the sudden onset of water retention yesterday seemed unusual. Anyone have any thoughts or experiences with this while on Clomid? I’m also still feeling very foggy with a big lack in focus and memory. I’m hoping this is due to the Clomid treatment rather than low “T”.
Also, below is my PCT regimen for the next 6 weeks. Any feedback is obviously welcome.
Week# 1 – 100MG’s of Clomid
Week# 2 – 100MG’s of Clomid
Week# 3 – 50MG’s of Clomid
Week# 4 – 50MG’s of Clomid
Week# 5 – .50MG’s of Arimidex Week# 6 – .25MG’s of Arimidex every other day
Anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin) are members of the third generation of aromatase inhibitors that has now replaced aminoglutethimide (Cytadren), the progestins, and tamoxifen (Nolvadex) as the hormonal therapy of choice in estrogen-receptor-positive, postmenopausal, metastatic breast cancer. This article will review the role of aromatase in the pathogenesis of breast cancer and the results of recent studies that have established the role of its inhibitors in estrogen-receptor-positive breast cancer. We will also briefly outline the rationale and design of ongoing studies. [ONCOLOGY 15(8):965-979, 2001]